ORBi: Oltenfreiter R. - Synthesis, quality control and in vivo evaluation of [I-123] rhTIMP-2, a potential tumour-imaging agent

Reference : Synthesis, quality control and in vivo evaluation of [I-123] rhTIMP-2, a potential tumou...


	Document type :	Scientific journals : Article
	Discipline(s) :	Human health sciences : Pharmacy, pharmacology & toxicology Physical, chemical, mathematical & earth Sciences : Chemistry Life sciences : Biochemistry, biophysics & molecular biology
	To cite this reference:	http://hdl.handle.net/2268/109911

Title :	Synthesis, quality control and in vivo evaluation of [I-123] rhTIMP-2, a potential tumour-imaging agent
Language :	English
Author, co-author :	Oltenfreiter, R. [> > > >]
	Burvenich, I. [> > > >]
	Staelens, L. [> > > >]
	Lejeune, Annabelle [Université de Liège - ULg > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire >]
	Frankenne, F. [> >]
	Foidart, Jean-Michel [Université de Liège - ULg > Département des sciences cliniques > Gynécologie - Obstétrique >]
	Slegers, G. [> > > >]
Publication date :	Apr-2005
Journal title :	Journal of Labelled Compounds & Radiopharmaceuticals
Publisher :	John Wiley & Sons Ltd
Volume :	48
Issue/season :	5
Pages :	387-396
Audience :	International
ISSN :	0362-4803
City :	Chichester
Keywords :	[en] radiolabelled rhTIMP-2 ; iodine-123 ; in vivo biodistribution ; SPECT ; tumour imaging
Abstract :	[en] Matrix metalloproteinases (MMPs) are enzymes involved in the turnover of the extracellular matrix. Their overexpression in tumours may provide a target for diagnostic imaging by using labelled MMP inhibitors. MMPs are inhibited by endogenous tissue inhibitors of metalloproteinases (TIMPs). The enhanced production of MT1-MMP, located on the surface of cells within or in the direct vicinity of the tumour, and the high affinity interaction between TIMP-2 and MT1-MMP suggested that TIMP-2 could be a potential agent for non-invasive monitoring of cancer MMP levels, diagnosis of primary and secondary tumours and tumour response to MMP inhibitor therapy. There is also evidence that I-125-rhTIMP-2 internalizes, which is an important feature for its possible use as a radiotherapeuticum if labelled with I-131. Labelling of rhTIMP-2 was performed using the iodogen method resulting in a radiochemical yield of 51.1 +/- 11.8% (n = 5) and a radiochemical purity of > 98%. The trichloroacetic acid (TCA) precipitability of I-123 rhTIMP-2 was 95.2%. SDS-PAGE confirmed the correct size (21 kDa) of the purified I-123 rhTIMP-2 without degradation. HPLC showed one radioactive peak with a retention time corresponding to the nonlabelled rhTIMP-2. In vivo biodistribution showed no long-term accumulation in organs and the possibility to accumulate in the tumour. These results show the potential of I-123 rhTIMP-2 as tumour-imaging agent. Copyright (c) 2005 John Wiley
Permalink :	http://hdl.handle.net/2268/109911
DOI :	10.1002/jlcr.937

File(s) associated to this reference

Fulltext file(s):

	File	Commentary	Version	Size	Access
Restricted access	Oltenfreiter JLC 2005.pdf		Publisher postprint	151.15 kB	Request copy

All documents in ORBi are protected by a user license.

Dspace v1.5